Last update 24 Mar 2025

213Bi-CETN1 antibodies (RadImmune)

Overview

Basic Info

Drug Type
Radiolabeled antibody, Therapeutic radiopharmaceuticals
Synonyms-
Target
CETN1
Action
inhibitors
Mechanism
CETN1 inhibitors(centrin 1 inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease
Active Indication-
Inactive Indication
Pancreatic Ductal Adenocarcinoma
Originator Organization
Radimmune Therapeutics, Inc.Radimmune Therapeutics, Inc.StartupUniversity of SaskatchewanUniversity of Saskatchewan
Active Organization-
Inactive Organization
Radimmune Therapeutics, Inc.Radimmune Therapeutics, Inc.StartupUniversity of SaskatchewanUniversity of Saskatchewan
Drug Highest PhasePendingPreclinical
First Approval Date-
Regulation-

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

100 Clinical Results associated with 213Bi-CETN1 antibodies (RadImmune)
Login to view more data
100 Translational Medicine associated with 213Bi-CETN1 antibodies (RadImmune)
Login to view more data
100 Patents (Medical) associated with 213Bi-CETN1 antibodies (RadImmune)
Login to view more data
100 Deals associated with 213Bi-CETN1 antibodies (RadImmune)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic Ductal AdenocarcinomaPreclinical
United States
Radimmune Therapeutics, Inc.Radimmune Therapeutics, Inc.Startup
16 Jul 2019
Pancreatic Ductal AdenocarcinomaPreclinical
Canada
University of SaskatchewanUniversity of Saskatchewan
16 Jul 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free